Autonomix RF Neurolysis Study Selected as Top Abstract
THE WOODLANDS, Texas, March 4, 2026 Autonomix Medical, Inc. announced that its novel transvascular peripheral radiofrequency (RF) nerve neurolysis...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
THE WOODLANDS, Texas, March 4, 2026 Autonomix Medical, Inc. announced that its novel transvascular peripheral radiofrequency (RF) nerve neurolysis...
February 25, 2026 – The Woodlands, Texas, USA Autonomix Medical, Inc. has announced the release of a new CEO...
